60 studies on IGF-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 17 published IGF-1 COA source records from third-party laboratories, covering 10 publicly attributable vendor identities. Across 11 records with positive numeric purity, the arithmetic mean is 99.17%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2026-03-07. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-03-07. Aggregate calculated: 2026-10-18T05:13:50.395398+00:00. Calculation time is not a laboratory observation date.
Within that total, 6 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Recent source records: #86142 (99.81%) · #20106 (98.134%) · #15360 (98.134%) · #95781 (98.587%) · #23248 (99.456%) · #23216 (99.563%)
**Clinicians and researchers** targeting age-related cardiovascular decline now have a cellular mechanism — EPC restoration via `IGF-1` — to anchor therapeutic protocols around GH secretagogues or direct IGF-1 interve…
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension o…
**Elevated IGF-1 alone does not translate to clinically meaningful functional recovery** in frail elderly hip fracture patients — a finding that should temper enthusiasm for `GHSR` agonists in this population. The eme…
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wa…
These findings highlight a significant challenge for the long-term use of oral GHSs like MK-677 for growth promotion. While the compound can acutely stimulate a robust GH pulse, the body appears to develop a powerful …
For athletes and individuals using performance-enhancing peptides, this review underscores that sophisticated detection methods are already established for a wide array of compounds, including popular research peptide…
This hypothetical study highlights CJC-1295's potential as a long-acting growth hormone-releasing hormone (GHRH) analog, capable of providing sustained GH and IGF-1 elevation from a single dose. This sustained release…
If the trial yielded positive results, this study would validate an oral therapeutic approach for fibromyalgia, potentially offering a more convenient and accessible alternative to injectable growth hormone. An effect…
Free, no account — handy when you're working with IGF-1.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account